Table 1.
Characteristics of the IN-RANGE clinical cohort (N = 390).
| Characteristic | N (%) or Mean (SD) |
|---|---|
| Age (years) | 59.2 (15.0) |
| Female gender | 119 (31) |
| Race: | |
| African American | 174 (45) |
| Caucasian | 206 (53) |
| Other | 10 (3) |
| Body Mass Index: | |
| < 25 | 122 (32) |
| 25–30 | 125 (32) |
| > 30 | 140 (36) |
| Warfarin indication: | |
| Atrial fibrillation/flutter | 188 (48) |
| DVT/PE | 116 (30) |
| DCM/LV thrombosis | 26 (7) |
| Stroke/TIA | 22 (6) |
| Other | 38 (10) |
| Target INR 2–3 | 389 (99.7) |
| Maintenance dose (mg/wk) | 39.9 (22.0) |
| Previous use of warfarin | 96 (25) |
| History of hypertension | 192 (49) |
| History of diabetes | 107 (27) |
| History of PUD | 36 (9) |
| History of CHF | 78 (20) |
| > 1 Interacting medications | 210 (54) |
| Smoking status: | |
| Never smoked | 141 (36) |
| Past smoker | 185 (47) |
| Current smoker | 64 (16) |
| CYP2C9 genotype: | |
| *1*1 | 283 (76) |
| *1*2 | 59 (16) |
| *1*3 | 26 (7) |
| *2*3 | 3 (1) |
| VKORC1 −1639G>A genotype: | |
| GG | 209 (56) |
| GA | 149 (40) |
| AA | 15 (4) |
| Insurance status: | |
| Private | 215 (56) |
| Any VA | 107 (28) |
| Medicaid | 16 (4) |
| Medicare only | 17 (4) |
| None | 29 (8) |
| Employment status: | |
| Working | 128 (33) |
| Unemployed | 34 (9) |
| Retired | 143 (37) |
| Disabled | 81 (21) |
| Income per household member: | |
| < $15,000/year | 109 (33) |
| $15,000–$20,000/year | 99 (30) |
| > $20,000/year | 122 (37) |
| AC clinic site: | |
| HUP | 184 (47) |
| PVAMC | 137 (35) |
| Hershey | 69 (18) |
Abbreviations:anticoagulation (AC), congestive heart failure (CHF), deep vein thrombosis (DVT), dilated cardiomyopathy (DCM), Hospital of the University of Pennsylvania (HUP), left ventricular (LV), peptic ulcer disease (PUD), Philadelphia Veterans Administration Medical Center (PVAMC), pulmonary embolism (PE), and transient ischemic attack (TIA).